. Author manuscript; available in PMC: 2019 Jun 5.

Published in final edited form as: Adv Cancer Res. 2017 Dec 7;137:115–170. doi: 10.1016/bs.acr.2017.11.003

Table 3.

Current Clinical Trials With Different shRNA Delivery Platforms

Title	Recruitment	Conditions	Interventions
Bi-shRNA-furin and Granulocyte Macrophage Colony Stimulating Factor Tumor Cell Vaccine for Advanced Cancer	Active, not recruiting	Ewing’s Sarcoma, Nonsmall Cell Lung Cancer, Liver Cancer	Biological: Vigil™\|Biological: Vigil™\|Biological: Vigil™
Pbi-shRNA STMN1 LP in Advanced and/or Metastatic Cancer	Completed	Advanced Cancer Metastatic Cancer Solid Tumors	Biological: pbi- shRNA STMN1 LP
Pbi-shRNA™ EWS/ FLI1 Type 1 LPX in Advanced Ewing’s Sarcoma	Recruiting	Ewing’s Sarcoma	Biological: pbi- shRNA™ EWS/ FLI1 Type 1 LPX
Treatment of Chronic Lymphocytic Leukemia	Not yet recruiting	Leukemia, Lymphocytic, Chronic, B-cell	Genetic: shRNA
Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant	Recruiting	HIV Infection, Mature T cell and NK cell, and cancer	Lentivirus Vector CCR5 shRNA and other interventions

Data retrieved from www.clinicaltrial.gov on June 28, 2017.